Intravitreal Pegaptanib
Pre-clinicalWithdrawn 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myopic Choroidal Neovascular Membrane
Conditions
Myopic Choroidal Neovascular Membrane
Trial Timeline
Dec 1, 2010 → Jul 1, 2012
NCT ID
NCT01218230About Intravitreal Pegaptanib
Intravitreal Pegaptanib is a pre-clinical stage product being developed by Pfizer for Myopic Choroidal Neovascular Membrane. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01218230. Target conditions include Myopic Choroidal Neovascular Membrane.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01218230 | Pre-clinical | Withdrawn |
Competing Products
1 competing product in Myopic Choroidal Neovascular Membrane
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer | Pre-clinical | 20 |